Connection

Laure Gossec to Humans

This is a "connection" page, showing publications Laure Gossec has written about Humans.
Connection Strength

0.148
  1. Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. Arthritis Care Res (Hoboken). 2020 12; 72(12):1772-1779.
    View in: PubMed
    Score: 0.007
  2. Criteria for inclusion in programs of functional restoration for chronic low back pain: Pragmatic Study. Ann Phys Rehabil Med. 2020 May; 63(3):189-194.
    View in: PubMed
    Score: 0.007
  3. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. J Rheumatol. 2019 10; 46(10):1259-1267.
    View in: PubMed
    Score: 0.007
  4. Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. Clin Rheumatol. 2018 Oct; 37(10):2649-2657.
    View in: PubMed
    Score: 0.006
  5. Fears and beliefs of people living with rheumatoid arthritis: a systematic literature review. Adv Rheumatol. 2018 May 24; 58(1):1.
    View in: PubMed
    Score: 0.006
  6. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018 05; 14(5):405-417.
    View in: PubMed
    Score: 0.006
  7. Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. Clin Rheumatol. 2018 Jun; 37(6):1503-1510.
    View in: PubMed
    Score: 0.006
  8. The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries. Rheumatology (Oxford). 2018 02 01; 57(2):300-308.
    View in: PubMed
    Score: 0.006
  9. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018 01; 45(1):6-13.
    View in: PubMed
    Score: 0.006
  10. Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. Ann Rheum Dis. 2018 02; 77(2):258-263.
    View in: PubMed
    Score: 0.006
  11. Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet et al. Ann Rheum Dis. 2018 05; 77(5):e24.
    View in: PubMed
    Score: 0.006
  12. How are enthesitis, dactylitis and nail involvement measured and reported in recent clinical trials of psoriatic arthritis? A systematic literature review. Ann Rheum Dis. 2018 05; 77(5):782-783.
    View in: PubMed
    Score: 0.006
  13. Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients. Rheumatology (Oxford). 2017 06 01; 56(6):896-900.
    View in: PubMed
    Score: 0.006
  14. Psychometric properties of sleep and coping numeric rating scales in rheumatoid arthritis: a subanalysis of an etanercept trial. Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):786-790.
    View in: PubMed
    Score: 0.006
  15. Patient-reported outcomes in Asia: evaluation of the properties of the Rheumatoid Arthritis Impact of Disease (RAID) score in multiethnic Asian patients with rheumatoid arthritis. Clin Rheumatol. 2017 May; 36(5):1149-1154.
    View in: PubMed
    Score: 0.006
  16. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
    View in: PubMed
    Score: 0.002
  17. EULAR COVID-19 registry: lessons learnt and future considerations. Ann Rheum Dis. 2021 09; 80(9):1110-1115.
    View in: PubMed
    Score: 0.002
  18. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
    View in: PubMed
    Score: 0.002
  19. How COVID-19 is changing rheumatology clinical practice. Nat Rev Rheumatol. 2021 01; 17(1):11-15.
    View in: PubMed
    Score: 0.002
  20. Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Rheumatology (Oxford). 2020 07 01; 59(7):1495-1504.
    View in: PubMed
    Score: 0.002
  21. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020 07; 79(7):851-858.
    View in: PubMed
    Score: 0.002
  22. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
    View in: PubMed
    Score: 0.002
  23. Spinal-pelvic orientation: potential effect on the diagnosis of spondyloarthritis. Rheumatology (Oxford). 2020 01 01; 59(1):84-89.
    View in: PubMed
    Score: 0.002
  24. Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. J Rheumatol. 2020 06 01; 47(6):854-864.
    View in: PubMed
    Score: 0.002
  25. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open. 2019; 5(2):e001014.
    View in: PubMed
    Score: 0.002
  26. Psychometric properties and cross-language equivalence of the revised Bristol Rheumatoid Arthritis Fatigue and the Rheumatoid Arthritis Impact of Disease scales in rheumatoid arthritis. Qual Life Res. 2019 Sep; 28(9):2543-2552.
    View in: PubMed
    Score: 0.002
  27. Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. J Rheumatol. 2019 08; 46(8):1014-1020.
    View in: PubMed
    Score: 0.002
  28. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. J Rheumatol. 2019 08; 46(8):1021-1027.
    View in: PubMed
    Score: 0.002
  29. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. J Rheumatol. 2019 08; 46(8):1028-1035.
    View in: PubMed
    Score: 0.002
  30. Acute anterior uveitis in spondyloarthritis: a monocentric study of 301 patients. Clin Exp Rheumatol. 2019 Jan-Feb; 37(1):26-31.
    View in: PubMed
    Score: 0.002
  31. PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. J Rheumatol. 2019 08; 46(8):990-995.
    View in: PubMed
    Score: 0.002
  32. The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France. Adv Rheumatol. 2018 Oct 22; 58(1):33.
    View in: PubMed
    Score: 0.002
  33. The Portuguese Rheumatoid Arthritis Impact of Disease (RAID) score and its measurement equivalence in three countries: validation study using Rasch Models. Qual Life Res. 2018 Nov; 27(11):2909-2921.
    View in: PubMed
    Score: 0.002
  34. Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. Ann Rheum Dis. 2018 12; 77(12):1835-1836.
    View in: PubMed
    Score: 0.002
  35. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018 06 19; 20(1):129.
    View in: PubMed
    Score: 0.002
  36. Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis. Ann Rheum Dis. 2018 08; 77(8):1099-1106.
    View in: PubMed
    Score: 0.002
  37. The controversy of using PGA to define remission in RA. Nat Rev Rheumatol. 2018 03 21; 14(4):245.
    View in: PubMed
    Score: 0.002
  38. Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. Arthritis Care Res (Hoboken). 2018 03; 70(3):369-378.
    View in: PubMed
    Score: 0.002
  39. 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Ann Rheum Dis. 2018 04; 77(4):476-479.
    View in: PubMed
    Score: 0.001
  40. The impact of patient global assessment in the definition of remission as a predictor of long-term radiographic damage in patients with rheumatoid arthritis: protocol for an individual patient data meta-analysis. Acta Reumatol Port. 2018 Jan-Mar; 43(1):52-60.
    View in: PubMed
    Score: 0.001
  41. Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis. 2018 04; 77(4):533-540.
    View in: PubMed
    Score: 0.001
  42. An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS. Ann Rheum Dis. 2018 Jan; 77(1):124-127.
    View in: PubMed
    Score: 0.001
  43. A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. Semin Arthritis Rheum. 2018 04; 47(5):654-665.
    View in: PubMed
    Score: 0.001
  44. Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. Rheumatology (Oxford). 2017 09 01; 56(9):1573-1578.
    View in: PubMed
    Score: 0.001
  45. New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology (Oxford). 2017 08 01; 56(8):1251-1253.
    View in: PubMed
    Score: 0.001
  46. Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. J Rheumatol. 2017 Oct; 44(10):1544-1550.
    View in: PubMed
    Score: 0.001
  47. Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. J Rheumatol. 2017 Dec; 44(12):1889-1893.
    View in: PubMed
    Score: 0.001
  48. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. J Rheumatol. 2017 Oct; 44(10):1551-1559.
    View in: PubMed
    Score: 0.001
  49. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun; 76(6):960-977.
    View in: PubMed
    Score: 0.001
  50. Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. J Rheumatol. 2017 Oct; 44(10):1522-1528.
    View in: PubMed
    Score: 0.001
  51. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011 Apr; 63(4):557-63.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.